UBS Group’s Replimune Group REPL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.45M | Sell |
581,210
-23,103
| -4% | -$177K | ﹤0.01% | 4191 |
|
|
2025
Q4 | $5.87M | Sell |
604,313
-297,317
| -33% | -$2.53M | ﹤0.01% | 3868 |
|
|
2025
Q3 | $3.78M | Buy |
901,630
+658,233
| +270% | +$4.21M | ﹤0.01% | 4329 |
|
|
2025
Q2 | $2.26M | Buy |
243,397
+95,092
| +64% | +$830K | ﹤0.01% | 4685 |
|
|
2025
Q1 | $1.45M | Buy |
148,305
+52,858
| +55% | +$654K | ﹤0.01% | 4974 |
|
|
2024
Q4 | $1.16M | Buy |
95,447
+4,430
| +5% | +$53.8K | ﹤0.01% | 5197 |
|
|
2024
Q3 | $998K | Buy |
91,017
+67,790
| +292% | +$689K | ﹤0.01% | 4658 |
|
|
2024
Q2 | $209K | Sell |
23,227
-344,759
| -94% | -$2.4M | ﹤0.01% | 5631 |
|
|
2024
Q1 | $3.01M | Buy |
367,986
+147,559
| +67% | +$1.21M | ﹤0.01% | 3521 |
|
|
2023
Q4 | $1.86M | Buy |
220,427
+160,484
| +268% | +$1.86M | ﹤0.01% | 3903 |
|
|
2023
Q3 | $1.03M | Buy |
59,943
+32,209
| +116% | +$633K | ﹤0.01% | 4050 |
|
|
2023
Q2 | $644K | Sell |
27,734
-56,880
| -67% | -$1.11M | ﹤0.01% | 4605 |
|
|
2023
Q1 | $1.49M | Buy |
84,614
+25,153
| +42% | +$598K | ﹤0.01% | 3727 |
|
|
2022
Q4 | $1.62M | Buy |
59,461
+52,908
| +807% | +$1.1M | ﹤0.01% | 3596 |
|
|
2022
Q3 | $114K | Sell |
6,553
-21,544
| -77% | -$411K | ﹤0.01% | 5600 |
|
|
2022
Q2 | $491K | Sell |
28,097
-66,336
| -70% | -$1.09M | ﹤0.01% | 4269 |
|
|
2022
Q1 | $1.6M | Buy |
94,433
+31,507
| +50% | +$595K | ﹤0.01% | 3650 |
|
|
2021
Q4 | $1.71M | Buy |
62,926
+35,340
| +128% | +$1.06M | ﹤0.01% | 3882 |
|
|
2021
Q3 | $818K | Buy |
27,586
+19,513
| +242% | +$634K | ﹤0.01% | 4356 |
|
|
2021
Q2 | $310K | Sell |
8,073
-36,552
| -82% | -$1.25M | ﹤0.01% | 5069 |
|
|
2021
Q1 | $1.36M | Buy |
44,625
+41,970
| +1,581% | +$1.57M | ﹤0.01% | 3937 |
|
|
2020
Q4 | $101K | Buy |
+2,655
| New | +$111K | ﹤0.01% | 5680 |
|
|
2020
Q3 | – | Sell |
-6,622
| Closed | -$165K | – | 8341 |
|
|
2020
Q2 | $165K | Sell |
6,622
-33,716
| -84% | -$596K | ﹤0.01% | 4934 |
|
|
2020
Q1 | $402K | Buy |
40,338
+40,255
| +48,500% | +$600K | ﹤0.01% | 4155 |
|
|
2019
Q4 | $1K | Sell |
83
-4,224
| -98% | -$60.9K | ﹤0.01% | 7977 |
|
|
2019
Q3 | $60K | Buy |
+4,307
| New | +$52.9K | ﹤0.01% | 6092 |
|
|
2019
Q2 | – | Sell |
-1,058
| Closed | -$16K | – | 8107 |
|
|
2019
Q1 | $16K | Buy |
1,058
+58
| +6% | +$723 | ﹤0.01% | 6492 |
|
|
2018
Q4 | $10K | Sell |
1,000
-778
| -44% | -$10.5K | ﹤0.01% | 7239 |
|
|
2018
Q3 | $29K | Buy |
+1,778
| New | +$31.2K | ﹤0.01% | 6568 |
|
Other funds holding REPL
BBA
RI
SCM
FIS
VCM
UBS Group's REPL Position: Q1 2026 in Review
UBS Group reduced its Replimune Group (REPL) stake by 3.8% in Q1 2026, selling an estimated $177K and leaving 581,210 shares worth $4.45M. The position accounts for ﹤0.01% of the portfolio, ranked #4191.
UBS Group first reported a position in REPL in Q3 2018 and has held it in 29 quarters since. The position peaked at $5.87M in Q4 2025. 180 funds tracked by Wall St. Rank hold REPL as of Q1 2026.
- UBS Group held 581,210 shares of Replimune Group worth $4.45M as of Q1 2026.
- UBS Group sold 23,103 Replimune Group shares in Q1 2026, an estimated $177K.
- Replimune Group made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4191 holding.
- UBS Group first reported a position in Replimune Group in Q3 2018 and has held it in 29 quarters since.
- UBS Group's Replimune Group position peaked at $5.87M in Q4 2025.
- 180 funds tracked by Wall St. Rank held Replimune Group as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.